Home › Funds › Chesley Taft & Associates LLC › ABT
Chesley Taft & Associates LLC position in ABT
ABBOTT LABORATORIES · Health Care
Chesley Taft & Associates LLC reported holding 282,519 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$27.9M, representing 1.09% of its reported portfolio and ranking #23 among its reported holdings. Chesley Taft & Associates LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How Chesley Taft & Associates LLC's ABT position evolved
Chesley Taft & Associates LLC first disclosed a stake in ABT in Q3 2023 at 236,373 shares (US$22.9M). The position peaked in Q2 2025 at 232,664 shares, worth US$31.6M. Across 13 filings, Chesley Taft & Associates LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 282,519 shares valued at US$27.9M — an increase of 2,835 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 236.37K | $22.89M | New |
| Q4 2023 | 237.50K | $26.14M | Hold |
| Q1 2024 | 237.29K | $26.97M | Hold |
| Q2 2024 | 238.05K | $24.74M | Hold |
| Q3 2024 | 236.17K | $26.93M | Reduce |
| Q4 2024 | 237.66K | $26.88M | Add |
| Q1 2025 | 234.06K | $31.05M | Reduce |
| Q2 2025 | 232.66K | $31.64M | Reduce |
| Q3 2025 | 223.16K | $29.89M | Reduce |
| Q4 2025 | 241.77K | $30.29M | Add |
| Q1 2026 | 242.63K | $24.91M | Hold |
| Q2 2026 | 279.68K | $25.38M | Add |
| Q3 2026 | 282.52K | $27.92M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Chesley Taft & Associates LLC
FAQ
How long has Chesley Taft & Associates LLC held ABT?
Chesley Taft & Associates LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Chesley Taft & Associates LLC's current position in ABT?
As of Q3 2026, Chesley Taft & Associates LLC holds 282.52K shares of ABT (ABBOTT LABORATORIES), valued at $27.92M, representing 1.09% of its reported portfolio and ranking #23.
Has Chesley Taft & Associates LLC been buying or selling ABT?
In the latest 13F filing (Q3 2026), Chesley Taft & Associates LLC increased its position in ABT. The position peaked in Q2 2025 at 232.66K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.